<unk>  has been used to treat Chagas disease, when it is given for 30 to 60 days. However, long-term use of<unk>  does increase chances of adverse events like gastrointestinal and neurological side effects. Due to the low tolerance and completion rate of<unk> , benznidazole is now being more considered for those who have Chagas disease and require long-term treatment. In the United States<unk>  is indicated in children and adolescents (birth to less than 18 years of age and weighing at least for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi.<unk>  has also been used to treat African trypanosomiasis (sleeping sickness), and is active in the second stage of the disease (central nervous system involvement). When<unk>  is given on its own, about half of all patients will relapse, but the combination of melarsoprol with<unk>  appears to be efficacious. Trials are awaited comparing melarsoprol/nifurtimox against melarsoprol alone for African sleeping sickness. Combination therapy with eflornithine and<unk>  is safer and easier than treatment with eflornithine alone, and appears to be equally or more effective. It has been recommended as first-line treatment for second-stage African trypanosomiasis. Pregnancy and breastfeeding Use of<unk>  should be avoided in pregnant women due to limited use. There is limited data shown that<unk>  doses up to 15 mg/kg daily can cause adverse effects in breastfed infants. Other authors do not consider breastfeeding a contraindication during<unk>  use.
Nifurtimox
Telithromycin
Diquafosol
Miproxifene
Miproxifene phosphate
Dirithromycin
Roxithromycin
Prulifloxacin